Pioneers in
patient-based
drug discovery

for more efficient drugs

About us

We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.

Newsroom

Keep posted about
our latest developments
and achievements

Video: Ksilink x 2CRSI

Video: Ksilink x 2CRSI

Ksilink and 2CRSI – acting together to enable next generation medicine. Collaborating since more than 5 years with 2CRSI, Ksilink is honored to be now recognized as one of...

read more

They trust us

Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”

Jacques Volckmann, Head of R&D, Sanofi, France

“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”

Wolfram Zimmermann, CSO, Myriamed GmbH, Germany

“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”

Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany

“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”

Bert Klebl, Managing Director of Lead Discovery Center, Germany